A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2)

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3199-3208

  Wu, Baojian ^a   Jiang, Wen ^a   Yin, Taijun ^a   Gao, Song ^a   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

BCRP; efflux; glucuronidation; glucuronide; UGT1A9

Indexed keywords

6 HYDROXYFLAVONE; 6 HYDROXYFLAVONE GLUCURONIDE; BREAST CANCER RESISTANCE PROTEIN; FLAVONE DERIVATIVE; HYMECROMONE; HYMECROMONE GLUCURONIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EXCRETION; DRUG TRANSPORT; MEMBRANE VESICLE; PRIORITY JOURNAL; STEADY STATE; THEORETICAL STUDY; TRANSPORT KINETICS;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLAVONOIDS; GLUCURONIDES; HELA CELLS; HUMANS; NEOPLASM PROTEINS;

EID: 84867880421     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0817-2     Document Type: Article

References (34)

1. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22(47):7340-58.
2. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab. 2010;11(7):603-17.
3. Rosenberg MF, Bikadi Z, Chan J, Liu X, Ni Z, Cai X, Ford RC, Mao Q. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure. 2010;18(4):482-93.
4. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 2004;110(6):921-7.
5. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm. 2006;3(1):55-61.
6. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins 3rd JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004;64(20):7491-9.
7. Zhuang Y, Fraga CH, Hubbard KE, Hagedorn N, Panetta JC, Waters CM, Stewart CF. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res. 2006;66(23):11305-13.
8. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006;27(5):447-86.
9. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther. 2006;319(1):459-67.
10. Lee JK, Abe K, Bridges AS, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver. Drug Metab Dispos. 2009;37(9):1916-21.
11. Xu H, Kulkarni KH, Singh R, Yang Z, Wang SW, Tam VH, Hu M. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm. 2009;6(6):1703-15.
12. Wu B, Kulkarni K, Basu S, Zhang S, Hu M. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci. 2011;100(9):3655-81.
13. Horikawa M, Kato Y, Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res. 2002;19:1345-53.
14. Jeong EJ, Liu X, Jia X, Chen J, Hu M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr Drug Metab. 2005;6(5):455-68.
15. Liu Z, Hu M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol. 2007;3(3):389-406.
16. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, Ishikawa T, Tanabe S, Kohno S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001;288(4):827-32.
17. Jiang W, Xu B, Wu B, Yu R, Hu M. UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Drug Metab Dispos. 2012;40(2):336-45.
18. Joseph TB, Wang SW, Liu X, Kulkarni KH, Wang J, Xu H, Hu M. Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms. Mol Pharm. 2007;4(6):883-94.
19. Wu B, Xu B, Hu M. Regioselective glucuronidation of flavonols by six human UGT1A isoforms. Pharm Res. 2011;28(8):1905-18.
20. Blais A, Bissonnette P, Berteloot A. Common characteristics for Na + -dependent sugar transport in Caco-2 cells and human fetal colon. J Membr Biol. 1987;99(2):113-25.
21. Yamaguchi H, Yano I, Hashimoto Y, Inui KI. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000;295:360-6.
22. Sun H, Pang KS. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos. 2008;36(1):102-23.
23. Sun H, Zhang L, Chow EC, Lin G, Zuo Z, Pang KS. A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibition. J Pharmacol Exp Ther. 2008;326(1):117-26.
24. Wu B, Morrow JK, Singh R, Zhang S, Hu M. Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J Pharmacol Exp Ther. 2011;336(2):403-13.
25. Singh R, Wu B, Tang L, Liu Z, Hu M. Identification of the position of mono-O-glucuronide of flavones and flavonols by analyzing shift in online UV spectrum (lambdamax) generated from an online diode array detector. J Agric Food Chem. 2010;58(17):9384-95.
26. Singh R, Wu B, Tang L, Hu M. Uridine diposphate glucuronosyltransferases isoform-dependent regiospecificity of glucuronidation of flavonoids. J Agric Food Chem. 2011;59(13):7452-64.
27. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003;278:23529-37.
28. Hu Y, Sampson KE, Heyde BR, Mandrell KM, Li N, Zutshi A, Lai Y. Saturation of multidrug-resistant protein 2 (mrp2/abcc2)-mediated hepatobiliary secretion: nonlinear pharmacokinetics of a heterocyclic compound in rats after intravenous bolus administration. Drug Metab Dispos. 2009;37(4):841-6.
29. Pál A, Méhn D, Molnár E, Gedey S, Mészáros P, Nagy T, Glavinas H, Janáky T, von Richter O, Báthori G, Szente L, Krajcsi P. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2. J Pharmacol Exp Ther. 2007;321(3):1085-94.
30. Hallifax D, Houston JB. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos. 2006;34(4):724-6.
31. Zhou J, Tracy TS, Remmel RP. Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos. 2010;38(3):431-40.
32. Pick A, Klinkhammer W, Wiese M. Specific inhibitors of the breast cancer resistance protein (BCRP). ChemMedChem. 2010;5(9):1498-505.
33. Zhang S, Yang X, Coburn RA, Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol. 2005;70(4):627-39.
34. An G, Gallegos J, Morris ME. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab Dispos. 2011;39(3):426-32.